The Agency supports the activities of the European Commission in China.
The European Commission signed a 'consultation and cooperation mechanism' between the Directorate-General for Enterprise and Industry and the Chinese State Food and Drug Authority (SFDA) in 2007. This agreement includes specific interactions on pharmaceuticals and provides for annual meetings between the two parties. The Agency supports these meetings and any subsequent actions agreed, with particular focus on assisting with the implementation of similar good manufacturing practice (GMP) and good clinical practice (GCP) standards to those applied in the European Union, to facilitate the use of products and data coming from China and helping to ensure a global approach to the manufacture and supervision of medicinal products in the long term.
In 2010, the European Commission and the SFDA agreed a specific action plan on GMP and GCP inspections.
The Agency also provides support to conferences within the scope of the consultation and cooperation mechanism where representatives from SFDA are involved. The Agency also works closely with WHO to support its activities with the SFDA, providing support for training and capacity building activities, including the invitation of inspectors to annual GCP inspector training events and the hosting of training sessions for SFDA staff at their request.